COMPASS Pathways plc

CMPS

Held by 13 specialist biotech funds

High Convergence

13 funds opened new positions. Next phase3 readout (Psilocybin): May 2025. Short interest: 6.3% of float.

Medical - Care FacilitiesCEO: Kabir Kumar NathIPO: 2020Website ↗

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

COMPASS Pathways plc

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research